Based on the Illumina Inc stock forecast from 19 analysts, the average analyst target price for Illumina Inc is USD 160.65 over the next 12 months. Illumina Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Illumina Inc is Slightly Bearish, which is based on 5 positive signals and 8 negative signals. At the last closing, Illumina Inc’s stock price was USD 136.99. Illumina Inc’s stock price has changed by -3.69% over the past week, -5.66% over the past month and +46.74% over the last year.
No recent analyst target price found for Illumina Inc
No recent average analyst rating found for Illumina Inc
Company Overview Illumina Inc
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California. Read Less
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments a...Read More
Frequently Asked Questions About Illumina Inc (ILMN) Stock
Based on ratings from 19 analysts Illumina Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 18 buy, sell and 11 hold ratings.
Unfortunately we do not have enough data on ILMN's stock to indicate if its a good dividend stock.
Based on targets from 19 analysts, the average taret price for ILMN is USD 160.65 over the next 12 months. The maximum analyst target price is USD 252 while the minimum anlayst target price is USD 115.
ILMN stock's Price/Earning ratio is 91.22.
Our analysis grades ILMN stock's Price / Earning ratio at F. This means that ILMN stock's Price/Earning ratio is above 78% of the stocks in the Diagnostics & Research sector in the NSD exchange.
Based on this ILMN may be a overvalued for its sector.
The last closing price of ILMN's stock was USD 136.99.
The most recent market capitalization for ILMN is USD 23.86B.
Based on targets from 19 analysts, the average taret price for ILMN is projected at USD 160.65 over the next 12 months.
This means that ILMN's stock price may go up by +17.27% over the next 12 months.
We can't find any ETFs which contains Illumina Inc's stock.
As per our most recent records Illumina Inc has 10,590 Employees.
Illumina Inc's registered address is 5200 Illumina Way, San Diego, CA, United States, 92122.
You can get more information about it from Illumina Inc's website at https://www.illumina.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Illumina Inc (ILMN) Stock
Based on ratings from 19 analysts Illumina Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 18 buy, sell and 11 hold ratings.
Unfortunately we do not have enough data on ILMN's stock to indicate if its a good dividend stock.
Based on targets from 19 analysts, the average taret price for ILMN is USD 160.65 over the next 12 months. The maximum analyst target price is USD 252 while the minimum anlayst target price is USD 115.
ILMN stock's Price/Earning ratio is 91.22.
Our analysis grades ILMN stock's Price / Earning ratio at F. This means that ILMN stock's Price/Earning ratio is above 78% of the stocks in the Diagnostics & Research sector in the NSD exchange.
Based on this ILMN may be a overvalued for its sector.
The last closing price of ILMN's stock was USD 136.99.
The most recent market capitalization for ILMN is USD 23.86B.
Based on targets from 19 analysts, the average taret price for ILMN is projected at USD 160.65 over the next 12 months.
This means that ILMN's stock price may go up by +17.27% over the next 12 months.
We can't find any ETFs which contains Illumina Inc's stock.
As per our most recent records Illumina Inc has 10,590 Employees.
Illumina Inc's registered address is 5200 Illumina Way, San Diego, CA, United States, 92122.
You can get more information about it from Illumina Inc's website at https://www.illumina.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ILMN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
